News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,357 Results
Type
Article (5383)
Company Profile (22)
Press Release (219952)
Section
Business (82942)
Career Advice (573)
Deals (15182)
Drug Delivery (11)
Drug Development (19515)
Employer Resources (32)
FDA (3778)
Job Trends (4062)
News (121821)
Policy (7934)
Tag
Academia (311)
Alliances (14930)
Alzheimer's disease (223)
Approvals (3776)
Bankruptcy (95)
Best Places to Work (2987)
Biotechnology (24)
Breast cancer (37)
Cancer (294)
Cardiovascular disease (23)
Career advice (484)
Cell therapy (66)
Clinical research (16155)
Collaboration (104)
Compensation (87)
COVID-19 (344)
C-suite (55)
Data (360)
Diabetes (34)
Diagnostics (2029)
Earnings (40202)
Employer resources (33)
Events (37494)
Executive appointments (166)
FDA (3916)
Funding (113)
Gene therapy (30)
GLP-1 (115)
Government (469)
Healthcare (5202)
Infectious disease (356)
Interviews (73)
IPO (7810)
Job creations (1153)
Job search strategy (430)
Layoffs (99)
Legal (2568)
Lung cancer (30)
Manufacturing (38)
Medical device (3866)
Medtech (3867)
Mergers & acquisitions (7439)
Metabolic disorders (91)
Neuroscience (277)
NextGen Class of 2024 (1769)
Non-profit (774)
Northern California (601)
Obesity (46)
Opinion (34)
People (24477)
Phase I (4756)
Phase II (6946)
Phase III (5680)
Pipeline (271)
Postmarket research (687)
Preclinical (1869)
Press Release (66)
Radiopharmaceuticals (104)
Rare diseases (44)
Real estate (1889)
Regulatory (5147)
Research institute (311)
Resumes & cover letters (114)
Southern California (446)
Startups (1018)
United States (4744)
Vaccines (37)
Date
Last 7 days (170)
Last 30 days (654)
Last 365 days (11170)
2024 (11119)
2023 (13316)
2022 (18838)
2021 (19951)
2020 (18562)
2019 (13634)
2018 (10510)
2017 (10200)
2016 (9321)
2015 (12262)
2014 (9697)
2013 (7790)
2012 (8420)
2011 (8896)
2010 (8739)
Location
Africa (205)
Arizona (49)
Asia (11443)
Australia (1596)
California (1227)
Canada (509)
China (35)
Colorado (50)
Connecticut (68)
Europe (24454)
Florida (163)
Georgia (26)
Idaho (23)
Illinois (88)
Indiana (43)
Japan (39)
Kansas (23)
Maine (34)
Maryland (153)
Massachusetts (1016)
Michigan (67)
Minnesota (105)
New Jersey (388)
New York (328)
North Carolina (254)
Northern California (601)
Ohio (38)
Pennsylvania (245)
South America (355)
Southern California (446)
Texas (148)
Utah (35)
Washington State (111)
225,357 Results for "cvs caremark corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
July 30, 2024
·
12 min read
Drug Delivery
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
April 16, 2024
·
2 min read
·
Tristan Manalac
Pharmacy benefit managers
House Oversight Chair Calls on PBM Execs to Correct Testimonies
The chair of the House Committee on Oversight and Accountability wants the CEOs of CVS Caremark, Express Scripts and Optum Rx to fix statements they made in a hearing last month that contradicted the committee’s and Federal Trade Commission’s findings.
August 29, 2024
·
2 min read
·
Tristan Manalac
Biotech Beach
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
Arcutis Biotherapeutics, Inc. announced that ZORYVE® cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5.
July 17, 2023
·
5 min read
Business
AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report
CVS Caremark’s recent decision to take AbbVie’s Humira off its major formularies has caused the blockbuster to lose more market share to biosimilars, according to the latest report from Samsung Bioepis.
July 12, 2024
·
2 min read
·
Tristan Manalac
Pharmacy benefit managers
Cigna to Remove AbbVie’s Humira From Formularies, Putting More Pressure on Blockbuster
Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna’s Express Scripts is taking Humira off its major commercial formularies starting next year and focusing on more affordable biosimilar options.
August 27, 2024
·
2 min read
·
Tristan Manalac
Press Releases
CVS Health Announces Board Appointments
November 18, 2024
·
7 min read
Press Releases
CVS Health announces Pharmacy and Consumer Wellness leadership appointments
December 3, 2024
·
3 min read
CVS to Remove AbbVie’s Humira from Reimbursement Lists, Cover Biosimilars
The pharmacy benefit management subsidiary of CVS Health is favoring Humira’s biosimilars for its major formularies, with AbbVie’s branded product to be nixed on April 1, 2024.
January 4, 2024
·
3 min read
·
Tristan Manalac
GLP-1
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
October 21, 2024
·
1 min read
·
Heather McKenzie
1 of 22,536
Next
